Diagnostic value of serum NSE, and S-100β and inflammatory markers levels in epilepsy

To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100β levels in patients with emergency secondary epilepsy(SE).

This was a retrospective cohort of 120 patients with SE who received Sodium valproate compared with a group who received carbamazepine for different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumour necrosis factor (TNF)-α, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100β, total effective rate (TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later.

There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P> 0.05). The results showed that IL-2 of the Sodium valproate group (53.17± 4.95 μg/L) was lower versus Carbamazepine group (62.38± 4.83 μg/L) (P< 0.05). The IL-8 of the Sodium valproate group postoperatively (26.48± 2.73 μg/L) was lower versus the Carbamazepine group (33.54± 3.39 μg/L) (P< 0.05). Postoperatively, the TNF-α in Sodium valproate group (32.18± 4.26 μg/L) was lower versus the Carbamazepine group (41.03± 4.92 μg/L) (P< 0.05). The s-100β (0.29 ± 0.15 ) μg/L in the Sodium valproate group was lower versus the Carbamazepine group (0.54± 0.14) μg/L (P < 0.05). The TER of the Sodium valproate group (93.33% ) was higher versus the Carbamazepine group of 75% (P < 0 .0 5 ). The number of epileptic seizures in the Sodium valproate group was 0.81± 0.08 times per year versus 1.23± 0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53± 0.22 min/time) was shorter than that in the Carbamazepine group (3.08 ± 0.24 min/time).

Sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.